Johnson & Johnson (JNJ-N) Stock Predictions - Stockchase
WATCH LIST
410
Johnson & Johnson (JNJ-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Johnson & Johnson

JNJ-N

159 watching          
Join the Discussion

Johnson & Johnson (JNJ-N) SAVE Mar, 18, 2019, 3:34 pm

136.93 0.67 (0.49%)

About Johnson & Johnson (JNJ-N)

Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886. More at Wikipedia

What the experts are saying about JNJ-N



  • All
  • Filtered
Signal Opinion Expert
BUY
Johnson & Johnson(JNJ-N) 

February 12, 2019

It's in a great space now, healthcare, given demographics and technology. The lawsuit will linger for a long time, but it's not hugely material. JNJ is a healthcare conglomrerate with consumer, medical devices and pharma divisions. It's like an ETF. A fine healthcare stock. A long-term hold if you can weather volatility surrounding the lawsuit.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
It's in a great space now, healthcare, given demographics and technology. The lawsuit will linger for a long time, but it's not hugely material. JNJ is a healthcare conglomrerate with consumer, medical devices and pharma divisions. It's like an ETF. A fine healthcare stock. A long-term hold if you can weather volatility surrounding the lawsuit.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Zachary Curry

Chief Oper, Davis-Rea Ltd....

Price Price
$133.950
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

February 8, 2019

When to exit? He thinks you "go to war" with this stock. He sees 18% upside still for it. He would continue to hold it long term. He might trim some length if it makes a new high.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
When to exit? He thinks you "go to war" with this stock. He sees 18% upside still for it. He would continue to hold it long term. He might trim some length if it makes a new high.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$132.400
Owned Owned
Yes

DON'T BUY
Johnson & Johnson(JNJ-N) 

February 6, 2019

He likes it, but wouldn't buy it. Consumer, pharma and devices are their three divisions. Only the consumer division is a problem; it has a baby powder cancer issue which is tainting the overall brand. Another headwind is branding: brands aren't any better than generics, as consumers now realize.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He likes it, but wouldn't buy it. Consumer, pharma and devices are their three divisions. Only the consumer division is a problem; it has a baby powder cancer issue which is tainting the overall brand. Another headwind is branding: brands aren't any better than generics, as consumers now realize.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$133.000
Owned Owned
Unknown

COMMENT
Johnson & Johnson(JNJ-N) 

January 25, 2019

Trading at 15x earnings after a pullback. It's a complicated company with so many products and now has this talcum powder issue. You won't go too wrong owning this, but will this be a compounder? He doesn't know. It's probably undervalued because of the talcum-cancer scare; markets *always* overreact to bad news. Always.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Trading at 15x earnings after a pullback. It's a complicated company with so many products and now has this talcum powder issue. You won't go too wrong owning this, but will this be a compounder? He doesn't know. It's probably undervalued because of the talcum-cancer scare; markets *always* overreact to bad news. Always.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Barry Schwartz

CIO & Port, Baskin Wealth Manage...

Price Price
$128.230
Owned Owned
No

BUY
Johnson & Johnson(JNJ-N) 

January 22, 2019

They just reported solid earnings, though the stock was down today a bit. Has a wide product range sold in 200 countries. Solid and diversified. They raise their dividend every year and it rise again.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They just reported solid earnings, though the stock was down today a bit. Has a wide product range sold in 200 countries. Solid and diversified. They raise their dividend every year and it rise again.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Baskin

President, Baskin Wealth Manage...

Price Price
$128.800
Owned Owned
Unknown

BUY
Johnson & Johnson(JNJ-N) 

January 10, 2019

Would the hiccup they had with the baby powder be a problem for the company and it is safe to step in? - Still own this company. They had it for a couple of years. The company said the product is safe and they said that the evidence is in their side. It is a triple A rated company. Their pharmaceutical division is doing very well. The dividend is very attractive and with the pullback it is good to step in.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Would the hiccup they had with the baby powder be a problem for the company and it is safe to step in? - Still own this company. They had it for a couple of years. The company said the product is safe and they said that the evidence is in their side. It is a triple A rated company. Their pharmaceutical division is doing very well. The dividend is very attractive and with the pullback it is good to step in.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$129.710
Owned Owned
Yes

BUY on WEAKNESS
Johnson & Johnson(JNJ-N) 

December 20, 2018

One of the biggest companies in the world. Pharama and consumer products. They were hit with a multi-billion dollar law suit that their baby powder has chemicals in it rather than just talc.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
One of the biggest companies in the world. Pharama and consumer products. They were hit with a multi-billion dollar law suit that their baby powder has chemicals in it rather than just talc.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$128.270
Owned Owned
Unknown

DON'T BUY
Johnson & Johnson(JNJ-N) 

December 19, 2018

It is suffering from asbestos in their talcum powder. This issue goes back four decades. The company is doing major damage control and he is not sure how it will end up. He would stay way.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
It is suffering from asbestos in their talcum powder. This issue goes back four decades. The company is doing major damage control and he is not sure how it will end up. He would stay way.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$127.610
Owned Owned
No

BUY
Johnson & Johnson(JNJ-N) 

December 13, 2018

This is a portfolio anchor type of company. It is defensive and pays a great dividend for a US equity. If you want to make a bet on Pharma you would not use this one because there are two other businesses in there. These other two businesses give it some diversification. It is a good long term play.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
This is a portfolio anchor type of company. It is defensive and pays a great dividend for a US equity. If you want to make a bet on Pharma you would not use this one because there are two other businesses in there. These other two businesses give it some diversification. It is a good long term play.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$147.840
Owned Owned
No

HOLD
Johnson & Johnson(JNJ-N) 

November 16, 2018

Worries about if markets do sell off. It’s had a great run up. It would have to get above levels it’s at. He’d buy because it’s still trending higher, but with the caveat to be careful with the DOW and S&P if they start to sell off.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Worries about if markets do sell off. It’s had a great run up. It would have to get above levels it’s at. He’d buy because it’s still trending higher, but with the caveat to be careful with the DOW and S&P if they start to sell off.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Elliott Fishman

Director o, Trading Services Gro...

Price Price
$145.990
Owned Owned
Unknown

COMMENT
Johnson & Johnson(JNJ-N) 

November 12, 2018

Avoided today's sell-off. Chart has a fantastic uptrend since 2014, though it's been oversold and overbought in periods. Current price is just below its January peak. This year it has a cup and handle pattern, which is good. It's not testing its January high. JNJ come be a defensive play, or it could go sideways or even drift down.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Avoided today's sell-off. Chart has a fantastic uptrend since 2014, though it's been oversold and overbought in periods. Current price is just below its January peak. This year it has a cup and handle pattern, which is good. It's not testing its January high. JNJ come be a defensive play, or it could go sideways or even drift down.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$145.620
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

November 9, 2018

He is overweight in both pharmaceuticals and biotechnology. It is nearing a 52 week high. They have continuously raised the dividend. It is a defensive name. There are other names in this sector that he prefers.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He is overweight in both pharmaceuticals and biotechnology. It is nearing a 52 week high. They have continuously raised the dividend. It is a defensive name. There are other names in this sector that he prefers.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Rob Tetrault

Portfolio , Tetrault Wealth Advi...

Price Price
$145.340
Owned Owned
No

WEAK BUY
Johnson & Johnson(JNJ-N) 

October 23, 2018

Healthcare names are defensive and a portfolio needs them, but JNJ is flat YTD. If your portfolio is light in defensive names, then consider this. Buy according to your overall portfolio composition. Consumer and medical product
divisions have modest growth. Pharma is its big driver of growth.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Healthcare names are defensive and a portfolio needs them, but JNJ is flat YTD. If your portfolio is light in defensive names, then consider this. Buy according to your overall portfolio composition. Consumer and medical product
divisions have modest growth. Pharma is its big driver of growth.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$138.930
Owned Owned
No

BUY
Johnson & Johnson(JNJ-N) 

October 11, 2018

Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$133.840
Owned Owned
Yes

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

October 10, 2018

(Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive
environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive
environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$137.730
Owned Owned
Yes

BUY
Johnson & Johnson(JNJ-N) 

August 30, 2018

He loves it.  The judgment against them is not significant.  He has a model price of $160.81, a 20% upside.  It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He loves it.  The judgment against them is not significant.  He has a model price of $160.81, a 20% upside.  It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$134.950
Owned Owned
Unknown

COMMENT
Johnson & Johnson(JNJ-N) 

August 27, 2018

Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$134.920
Owned Owned
Unknown

TOP PICK
Johnson & Johnson(JNJ-N) 

July 10, 2018

Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$127.380
Owned Owned
Yes

BUY

It is a very well run company.  Pharma, medical supply and personal goods businesses.  The pharma business is doing well.  They have a number of drugs.  Brands are not as valued by millennials as by their predecessors.  This is the struggle that JNJ-N is having.  They have a strong balance sheet and a nice dividend.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

It is a very well run company.  Pharma, medical supply and personal goods businesses.  The pharma business is doing well.  They have a number of drugs.  Brands are not as valued by millennials as by their predecessors.  This is the struggle that JNJ-N is having.  They have a strong balance sheet and a nice dividend.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$123.330
Owned Owned
Unknown

PAST TOP PICK

(Past Top Pick on May 16, 2017, Down 1.5%)  Their pharma side and newly released drugs are doing very well which offsets their drugs that are going generic. They have a solid pipeline of 10 new drugs over the next few years, each drug expected to make $1-billion. They invest in R&D and buy companies occasionally, including one last year.  Yield under 3%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Past Top Pick on May 16, 2017, Down 1.5%)  Their pharma side and newly released drugs are doing very well which offsets their drugs that are going generic. They have a solid pipeline of 10 new drugs over the next few years, each drug expected to make $1-billion. They invest in R&D and buy companies occasionally, including one last year.  Yield under 3%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$122.610
Owned Owned
Yes

BUY
Johnson & Johnson(JNJ-N) 

April 27, 2018

This is one of the “bluest” blue chip with a AAA credit rating.  Consumer staples companies have had a tough time this year.  It is a fabulous company and has several levers it could pull to unlock value.  It is a good defensive investment with a good yield. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This is one of the “bluest” blue chip with a AAA credit rating.  Consumer staples companies have had a tough time this year.  It is a fabulous company and has several levers it could pull to unlock value.  It is a good defensive investment with a good yield. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Dietze

Founder, P, Point View Wealth Ma...

Price Price
$128.270
Owned Owned
Yes

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

April 16, 2018

(A Past Top Pick on May 16, 2017, Up 6%) Expects tomorrow's Q1 report to be good. They're seeing good growth in their pharmaceutical division. They invest in their pipeline, so there's organic growth; They also make strategic acquisitions, like a Swiss biotech last year that focuses on heart diseases. In the pharma side, their investments are starting to pay off and offsetting some of their drugs going generic. A defensive play with strong financials.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Past Top Pick on May 16, 2017, Up 6%) Expects tomorrow's Q1 report to be good. They're seeing good growth in their pharmaceutical division. They invest in their pipeline, so there's organic growth; They also make strategic acquisitions, like a Swiss biotech last year that focuses on heart diseases. In the pharma side, their investments are starting to pay off and offsetting some of their drugs going generic. A defensive play with strong financials.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$131.760
Owned Owned
Yes

BUY
Johnson & Johnson(JNJ-N) 

March 21, 2018

Long-term, this is the one to own. A dominant player in medtech and pharma. 10% of their revenue has been from one drug. Competition is weak. A well-run, large company. Valuations are okay. An anchor in his portfolio. Their diversified
portolio of drugs can withstand the failure of one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Long-term, this is the one to own. A dominant player in medtech and pharma. 10% of their revenue has been from one drug. Competition is weak. A well-run, large company. Valuations are okay. An anchor in his portfolio. Their diversified
portolio of drugs can withstand the failure of one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$131.190
Owned Owned
Yes

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

February 13, 2018

(A Top Pick February 17, 2017. Up 11.49%). Still likes it and added to her portfolio as it pulled back last week. Their pharma business is doing quite well. This is their highest-margin business. They invest about 13% of revenues into R&D, which supports a strong pipeline. They will use some of their strong cash flow to pay down debt. Their dividend, 2%, has grown every year for 55 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick February 17, 2017. Up 11.49%). Still likes it and added to her portfolio as it pulled back last week. Their pharma business is doing quite well. This is their highest-margin business. They invest about 13% of revenues into R&D, which supports a strong pipeline. They will use some of their strong cash flow to pay down debt. Their dividend, 2%, has grown every year for 55 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$129.960
Owned Owned
Yes

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

February 7, 2018

(A Top Pick April 20/17, Up 10%) Recent pullback partially due to scare about their talcum powder. JNJ is the biggest, most diversified healthcare company in the world. Deserves to trade at a premium—16 times next year earnings. It should be worth more. Divident solid. Great pipeline in pharmaceuticals and medical devices. Healthcare is his biggest overweight in the U.S.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick April 20/17, Up 10%) Recent pullback partially due to scare about their talcum powder. JNJ is the biggest, most diversified healthcare company in the world. Deserves to trade at a premium—16 times next year earnings. It should be worth more. Divident solid. Great pipeline in pharmaceuticals and medical devices. Healthcare is his biggest overweight in the U.S.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Zeiler

Portfolio , TriDelta Financial...

Price Price
$131.420
Owned Owned
Unknown

WEAK BUY
Johnson & Johnson(JNJ-N) 

February 6, 2018

Has dropped, along with everything else. You have to consider whether it is cheap at this level. If you look beyond the past few days, you will see that at the beginning of 2017, it was trading at about $100 per share. Now it is over $128, so today’s price is significantly increased over a short time. The business trades at a low multiple at this level (15 to 16 times earnings), near “cheap” levels. JNJ is made up of three businesses: pharma, consumer products and medical devices. The company might be more interesting if it split these into separate businesses. He doesn’t think investors will go wrong by holding this company as is, but this is not a pound-the-table opportunity at this price.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Has dropped, along with everything else. You have to consider whether it is cheap at this level. If you look beyond the past few days, you will see that at the beginning of 2017, it was trading at about $100 per share. Now it is over $128, so today’s price is significantly increased over a short time. The business trades at a low multiple at this level (15 to 16 times earnings), near “cheap” levels. JNJ is made up of three businesses: pharma, consumer products and medical devices. The company might be more interesting if it split these into separate businesses. He doesn’t think investors will go wrong by holding this company as is, but this is not a pound-the-table opportunity at this price.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$131.830
Owned Owned
No

BUY
Johnson & Johnson(JNJ-N) 

February 1, 2018

They owned it and sold it moving the money to another pharmaceutical that was offering better value. Good company. 2.4% dividend yield. Trades at 17 earnings. Had a higher multiple not long ago. Unique in the sense that has three different businesses: pharma, consumer products and medical devices. Those three together has made it very profitable and diversified. Increase its dividend for the last 15 years in a row. They make good small acquisitions. If the market pull back, it is a protective stock as it won’t collapse. Very stable business.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They owned it and sold it moving the money to another pharmaceutical that was offering better value. Good company. 2.4% dividend yield. Trades at 17 earnings. Had a higher multiple not long ago. Unique in the sense that has three different businesses: pharma, consumer products and medical devices. Those three together has made it very profitable and diversified. Increase its dividend for the last 15 years in a row. They make good small acquisitions. If the market pull back, it is a protective stock as it won’t collapse. Very stable business.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$140.020
Owned Owned
No

BUY
Johnson & Johnson(JNJ-N) 

January 9, 2018

She likes this, because their pharmacy division is doing very well in terms of product pipeline development and new products they’ve launched in the last 2 years. Their Pharma division is the most profitable and very beneficial to the bottom line. This will be benefiting from the US tax cuts. An attractive yield of 2.4%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

She likes this, because their pharmacy division is doing very well in terms of product pipeline development and new products they’ve launched in the last 2 years. Their Pharma division is the most profitable and very beneficial to the bottom line. This will be benefiting from the US tax cuts. An attractive yield of 2.4%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$144.140
Owned Owned
Yes

HOLD
Johnson & Johnson(JNJ-N) 

December 14, 2017

A very large US company.  Pharma, consumer products and medical devices.  Great balance sheet, triple ‘A” rated.  The first two areas are doing well right now, but have done better.  Expect good earnings and cash flow.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A very large US company.  Pharma, consumer products and medical devices.  Great balance sheet, triple ‘A” rated.  The first two areas are doing well right now, but have done better.  Expect good earnings and cash flow.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Michael Simpson

Senior Vic, Sentry Investments...

Price Price
$141.650
Owned Owned
Unknown

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

December 12, 2017

(A Top Pick Dec 14/16. Up 28%.) She continues to like this. All 3 divisions are doing well, but their pharmaceutical division is doing particularly well.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Dec 14/16. Up 28%.) She continues to like this. All 3 divisions are doing well, but their pharmaceutical division is doing particularly well.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$142.600
Owned Owned
Yes

Showing 1 to 30 of 410 entries
Successfully Saved Company
Successfully Saved Company